Perlmutter Cancer Center at NYU Langone | Strategic Alliance Partners

Latest from Perlmutter Cancer Center at NYU Langone


Neel on Maximizing Research Strides in Oncology

September 16, 2021

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

Gynecologic Oncology Pioneer Franco Muggia Dies at 85

September 10, 2021

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.

Triplet Combination Safe, Effective for Relapsed/Refractory DLBCL

June 05, 2021

Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.

Dostarlimab Delivers Durable Responses in dMMR/MMRp Endometrial Cancer

March 24, 2021

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer

February 13, 2021

February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.